BPC-157

Buy BPC-157 Online

Book Now

Questions about peptides? Click here to schedule a free consultation with a physician.

Our Price $49.99 Price Match Promise Found a lower price? We'll match it.
x
Secure Encrypted Payments

BPC-157 is a synthetic peptide also known as Body Protection Compound-157 or pentadecapeptide BPC-157. It can be ordered online, with current BPC-157 price and quantity information shown during checkout. This peptide is supplied for research use only and is not intended for human consumption, self-administration, therapeutic use, veterinary use, diagnostic procedures, or personal treatment.

BPC-157 is widely discussed online in connection with tendon repair, muscle recovery, joint pain, gastrointestinal protection, and inflammation. Those discussions often mix early research findings with personal-use claims, so the product should be evaluated by its actual identity, handling requirements, and research-use status rather than by testimonials or social media claims.

BPC-157 Price, Ordering, and Product Selection

BPC-157 cost can vary by quantity, presentation, and the current ordering information shown at purchase. Match the product name, total contents, storage instructions, and any batch information to the intended research context. Do not treat online references to BPC-157 capsules, tablets, powders, supplements, or injections as interchangeable unless the actual product documentation supports that form.

When you buy BPC-157 online, keep the selection tied to the material being offered rather than to claims about BPC-157 benefits. The terms Body Protection Compound 157, pentadecapeptide BPC 157, and BPC-157 peptide may refer to the same peptide identity, but wording alone does not confirm a strength, format, route, or suitability for personal use. US delivery from Canada may be part of the service context, and prompt, express shipping may be referenced during ordering.

For broader browsing, the peptides category groups related peptide products. Category navigation can help organize adjacent compounds, but it should not replace careful review of product identity, storage requirements, safety boundaries, or the difference between research availability and approved treatment.

Quick tip: Save the product name, order date, quantity, and lot information if provided so the material remains traceable after delivery.

Research-Use Status, Trials, and Treatment Claims

BPC-157 is not offered here as an approved medication for tendon repair, joint pain, muscle recovery, stomach problems, inflammation, neurological symptoms, or recovery after injury. Research peptide availability, clinical trial participation, and approved medical treatment are separate pathways. Ordering a research-use peptide does not mean it has been evaluated for personal dosing, safety, effectiveness, or treatment use.

Questions such as whether BPC-157 can be taken every day, what dosage to use, or how long it takes to work cannot be answered responsibly from a research product context. Human-use dosing has not been established through the type of clinical evaluation expected for approved medicines. Anyone considering peptide exposure for a health reason should speak with a qualified healthcare professional instead of relying on BPC-157 reviews, before-and-after posts, or influencer protocols.

Clinical trial access is also different from buying a peptide for research purposes. Trial participation, when available, is governed by a study sponsor, eligibility criteria, informed consent, and medical oversight. A research-use product should not be used as a substitute for enrollment in a legitimate clinical study or for care from a licensed clinician.

Research-Grade Product Profile

BPC-157 is a synthetic pentadecapeptide made of 15 amino acids. It was derived from a protein fragment associated with gastric secretions and has attracted scientific interest because of its stability in biological research environments. Preclinical literature has examined possible roles in tissue remodeling, vascular signaling, gastrointestinal integrity, and neurobiological pathways.

The compound is often described as a “healing peptide,” but that phrase can overstate what is known. Most evidence comes from cell, tissue, or animal models, and those findings do not prove that BPC-157 is safe or effective for people. Human-use claims remain unsettled, especially when products are promoted as supplements, recovery aids, or anti-aging treatments.

ParameterSpecification
Product NameBPC-157
Alternative NamesBody Protection Compound-157, Pentadecapeptide BPC-157
Peptide Length15 amino acids
Molecular FormulaC62H98N16O22
Molecular Weight1419.55 g/mol
Peptide TypeSynthetic pentadecapeptide
PurityResearch grade
Storage ConditionsStore refrigerated as specified on product documentation
Intended UseResearch use only

Pathways and Research Areas Under Investigation

BPC-157 has been studied in experimental systems related to cellular repair processes and tissue remodeling. Reported research areas include collagen deposition, extracellular matrix formation, fibroblast migration, angiogenesis, oxidative stress responses, inflammatory signaling, and cell survival. These endpoints describe research observations, not instructions for personal use.

In tendon and ligament models, studies have examined tendon-derived fibroblast migration, cell survival, and outgrowth under controlled experimental conditions. Pathways such as focal adhesion kinase and paxillin have been investigated because they help regulate cell attachment, movement, and structural organization. The ligament healing category may help organize related topics, but it should not be read as evidence that BPC-157 treats ligament injuries in people.

Gastrointestinal research has also been a major focus. BPC-157 was originally associated with gastric tissue research, and preclinical work has evaluated models involving gastric injury, intestinal lesions, esophageal damage, duodenal healing, and inflammatory gastrointestinal conditions. Reported findings around mucosal integrity remain part of ongoing scientific investigation.

  • Angiogenesis and vascular development models
  • Fibroblast migration and cell attachment research
  • Collagen and extracellular matrix studies
  • Gastrointestinal mucosal integrity models
  • Oxidative stress and cell survival experiments
  • Neurovascular and neurotransmitter pathway research

Because these pathways overlap with repair and inflammatory biology, BPC-157 research can intersect with many scientific themes. The inflammation category can support topic browsing, but inflammation-related research does not establish a clinical role for this peptide.

Tendon, Muscle, Joint, and Recovery Discussions

BPC-157 is commonly searched alongside tendon repair, muscle recovery, joint pain, and injury healing. Those interests reflect the way the peptide is discussed in preclinical literature and wellness marketing. They do not mean the product is approved for athletes, active adults, surgical recovery, chronic pain, arthritis, digestive symptoms, or general recovery goals.

Muscle recovery models have examined structural repair and functional restoration after experimental injury. Some studies have described favorable tissue outcomes in settings where healing was impaired. These findings do not confirm that BPC-157 improves muscle recovery in humans, reduces soreness, prevents injury, or speeds return to activity.

Joint pain and tendon problems can have many causes, including inflammation, degeneration, autoimmune disease, overuse, infection, and mechanical injury. A clinician can evaluate the cause and recommend evidence-based care. Self-directed peptide use may delay diagnosis, complicate treatment, or add risks from an unknown product source, improper handling, contamination, or interactions with other substances.

Safety, Side Effects, and Personal Risk Factors

BPC-157 safety for human use has not been established through the kind of clinical evaluation expected for approved medications. Limited human data mean possible side effects, kidney effects, heart effects, immune reactions, injection-related harms, contamination risks, and drug interactions are not fully understood. Do not use this research peptide for self-directed treatment or personal dosing.

People often ask whether BPC-157 is hard on kidneys or what it does to the heart. Those questions do not have reliable, product-specific answers for personal use because controlled human safety evidence is limited. Kidney disease, cardiovascular disease, blood pressure problems, diabetes, immune conditions, pregnancy, planned surgery, and the use of multiple medicines can all change personal risk.

Anyone who has used or is considering peptide products should tell a healthcare professional about all medicines, supplements, hormones, over-the-counter products, and experimental compounds. This is especially important for people using blood thinners, diabetes medicines, blood pressure treatments, immune-modifying therapies, or drugs with narrow safety margins. Interaction risks may be missed when peptide use is not disclosed.

Seek urgent medical help for severe allergic symptoms, chest pain, breathing difficulty, fainting, severe swelling, neurological symptoms, signs of infection, or rapidly worsening pain. These symptoms need medical assessment rather than online troubleshooting, repeat exposure, or changes based on anecdotal BPC-157 reviews.

Why it matters: Research-only labeling helps prevent uncertain laboratory findings from becoming unsafe personal treatment decisions.

Handling, Storage, and Documentation

Store BPC-157 refrigerated as specified on the product documentation. Avoid unnecessary temperature changes, repeated handling, contamination, and informal transfers. Follow the handling instructions associated with the product and use appropriate protective measures for peptide materials.

Good documentation supports traceability and quality control. Track the product name, supplier, order date, lot number if available, storage location, date opened, and handling notes. Record any deviations from expected storage or handling conditions because those details can affect interpretation and safety review.

Do not rely on forum posts to decide whether a peptide is still suitable after heat exposure, prolonged storage, reconstitution, or visible changes. The correct approach depends on product documentation and material handling standards. If storage conditions are uncertain, treat the material cautiously rather than assuming potency, purity, or safety.

Quality Standards for Research Peptides

Research peptide selection should prioritize identity, traceability, and documented handling. BPC-157 is a small synthetic peptide, and small differences in manufacturing, storage, labeling, or contamination can affect interpretation. Batch documentation, purity information, and storage instructions should be kept whenever available.

Similar names can create confusion. Body Protection Compound-157, pentadecapeptide BPC-157, and BPC-157 refer to the same peptide identity in this context, but related peptides may have different sequences, proposed mechanisms, and handling requirements. Treat each compound as a separate material with its own documentation.

Wellness-market claims can be especially misleading when they promise recovery, pain relief, gut healing, anti-aging effects, or performance benefits. Commercial claims are not a substitute for peer-reviewed evidence, appropriate safety review, and clear separation between research use and personal treatment.

Related Peptide Research Options

Related peptide products can help organize research questions, but they should not be swapped without scientific review. Different peptides may have different sequences, proposed pathways, storage needs, and safety uncertainties. Product names that appear together in wellness discussions may not serve the same purpose.

TB-500 is a separate peptide listing and is not a direct replacement for BPC-157. Review each material on its own terms, including peptide identity, intended research use, documentation, and storage instructions. Ipamorelin is another peptide product with a different research context and should be evaluated separately rather than grouped with tissue-repair discussions.

For patient-friendly background on why peptide discussions differ from approved medication decisions, Peptides Explained: A Practical Guide for Patients may help frame safer questions for a clinician. Educational content can support informed conversations, but it should not be used to justify unsupervised peptide use.

Authoritative Sources

Independent safety context is important because BPC-157 is widely promoted online despite unsettled human-use evidence. The OPSS summary on BPC-157 safety and status explains concerns about prohibited peptide products and unapproved drug claims. A peer-reviewed narrative review of BPC-157 research and risk discusses the scientific literature and uncertainty around human-use claims.

Use these sources to support careful evaluation and clinician conversations. They should not be used to create self-treatment plans, determine personal dosage, or replace medical evaluation for pain, injury, digestive symptoms, cardiovascular concerns, kidney questions, or recovery goals.

This content is for informational purposes only and is not a substitute for professional medical advice.

Research & Education Tool

BPC-157 Dosage Calculator

Enter the vial amount, diluent volume, syringe size, and target amount to estimate concentration, draw volume, and approximate vial yield.

For research and educational use only. Check all values against the product label, certificate of analysis, and any applicable professional guidance before relying on the result.

mg

Concentration - mcg / mL
Volume per Dose - -
Estimated Draws / Vial - rounded down to whole draws

Click here to order.

Draw Reference

Enter values to estimate the syringe mark.

0 - - - -

Express Shipping - from $29.99

Shipping with this method takes 3-5 days

Prices:
  • Dry-Packed Products $29.99
  • Cold-Packed Products $39.99
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Standard Shipping - $19.99

Shipping with this method takes 5-10 days

Prices:
  • Dry-Packed Products $19.99
  • Not available for Cold-Packed products
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Rewards Program

Earn points on birthdays, product orders, reviews, friend referrals, and more! Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us.

You can read more about rewards here.

POINT VALUE

100 points
1 USD

How to earn points

  • 1Register and/or Login
    Create an account and start earning.
  • 2Earn Rewards
    Earn points every time you shop or perform certain actions.
  • 3Redeem
    Redeem points for exclusive discounts.

You Might Also Like

DSIP

$35.14

  • In Stock
  • Express Shipping
US $1,743.98
Our Price $35.14
Select options This product has multiple variants. The options may be chosen on the product page
Ipamorelin

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
Cagrilintide

$186.19

  • In Stock
  • Express Shipping
Our Price $186.19
Select options This product has multiple variants. The options may be chosen on the product page
Tesamorelin

$75.99

  • In Stock
  • Express Shipping
US $6,040.69
Our Price $75.99
Select options This product has multiple variants. The options may be chosen on the product page

Peptide Screening Form

Patient Information

Please provide your basic demographic information.

Type your date of birth in MM/DD/YYYY format.

Peptides of Interest

Peptides of Interest

Select the peptides you are interested in or have been recommended.

Medical History & Screening

Medical History & Screening

Please indicate if any of the following apply to you. Red flag alerts will appear if a condition contraindicates any of the available peptide therapies.

Contraindicated for CJC-1295: Growth hormone-releasing peptides like CJC-1295 are contraindicated in patients with active cancer because they may promote cell proliferation and tumor growth.

Contraindicated for Ipamorelin: Ipamorelin stimulates growth hormone release, which may promote tumor growth and cell proliferation in active cancers.

Contraindicated for Sermorelin: Sermorelin increases growth hormone production, which may stimulate growth of existing tumors.

Contraindicated for BPC-157: BPC-157 promotes angiogenesis (new blood vessel formation), which could support tumor growth and metastasis in active cancers.

Contraindicated for AOD-9604: Although AOD-9604 is a modified GH fragment, it may still interact with growth-related pathways in patients with active malignancies.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 promotes cell migration and angiogenesis, which may facilitate tumor growth and metastasis in active cancers.

Contraindicated for GHK-Cu: GHK-Cu promotes angiogenesis and tissue remodeling, which may support tumor growth in patients with active cancer.

Contraindicated for Epithalon (Epitalon): Epithalon stimulates telomerase activity. Cancer cells exploit telomerase to achieve immortality, potentially accelerating tumor growth.

Contraindicated for Semax: Semax has neurotrophic properties that promote cell growth, which may be concerning in patients with active malignancies.

Contraindicated for MOTS-c: MOTS-c influences cellular metabolism and AMPK pathways. Effects on cancer cell metabolism are not fully understood.

Contraindicated for Tesamorelin: Tesamorelin stimulates growth hormone release, which may promote tumor growth in patients with active malignancies.

Contraindicated for Hexarelin: Hexarelin stimulates growth hormone release, which may promote tumor growth and cell proliferation.

Contraindicated for GHRP-6: GHRP-6 stimulates growth hormone release, which may promote tumor growth in active cancers.

Contraindicated for GHRP-2: GHRP-2 stimulates growth hormone release, which may promote tumor growth in active malignancies.

Contraindicated for Melanotan II: Melanotan II stimulates melanocyte activity. In patients with skin cancers, particularly melanoma, it may accelerate disease progression.

Contraindicated for Dihexa: Dihexa activates hepatocyte growth factor (HGF) pathways, which can promote tumor growth and metastasis.

Contraindicated for Kisspeptin-10: Kisspeptin-10 influences reproductive hormone pathways. Hormone-sensitive cancers may be affected by altered GnRH and gonadotropin levels.

Contraindicated for Humanin: Humanin has anti-apoptotic properties that may protect cancer cells from programmed cell death, potentially supporting tumor survival.

Contraindicated for Retatrutide: Retatrutide acts on multiple metabolic pathways including GLP-1 and GIP receptors. Its effects on cell proliferation in patients with active malignancies have not been fully characterized.

Contraindicated for CJC-1295: CJC-1295 stimulates growth hormone release, which can increase IGF-1 levels. Elevated IGF-1 has been associated with cancer recurrence.

Contraindicated for Ipamorelin: The growth hormone and IGF-1 elevation from Ipamorelin may increase the risk of cancer recurrence.

Contraindicated for Sermorelin: Growth hormone stimulation from Sermorelin elevates IGF-1, which has been linked to increased cancer recurrence risk.

Contraindicated for BPC-157: The pro-angiogenic properties of BPC-157 may potentially support recurrence by promoting blood vessel growth that could feed dormant cancer cells.

Contraindicated for TB-500 (Thymosin Beta-4): The pro-angiogenic and cell-migration properties of TB-500 may increase the risk of cancer recurrence.

Contraindicated for Epithalon (Epitalon): Telomerase activation from Epithalon may increase the risk of cancer recurrence by supporting abnormal cell survival.

Contraindicated for Tesamorelin: Growth hormone and IGF-1 elevation from Tesamorelin may increase risk of cancer recurrence.

Contraindicated for Hexarelin: Elevated growth hormone and IGF-1 from Hexarelin may increase risk of cancer recurrence.

Contraindicated for GHRP-6: Growth hormone and IGF-1 elevation from GHRP-6 may increase risk of cancer recurrence.

Contraindicated for GHRP-2: Elevated IGF-1 from GHRP-2-stimulated growth hormone may increase cancer recurrence risk.

Contraindicated for Melanotan II: Melanocortin stimulation from Melanotan II may increase melanoma recurrence risk in patients with skin cancer history.

Contraindicated for Dihexa: HGF pathway activation from Dihexa may increase cancer recurrence risk through pro-growth signaling.

Contraindicated for Humanin: The cytoprotective effects of Humanin may increase cancer recurrence risk by inhibiting apoptosis in dormant cancer cells.

Contraindicated for Retatrutide: GLP-1 receptor agonists have been linked to thyroid C-cell tumors in animal studies. Retatrutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Contraindicated for Retatrutide: Retatrutide is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the risk of medullary thyroid carcinoma associated with GLP-1 receptor agonists.

Contraindicated for CJC-1295: CJC-1295 has not been studied in pregnancy and may affect fetal development through altered growth hormone levels.

Contraindicated for Ipamorelin: Ipamorelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for Sermorelin: Sermorelin is not approved for use during pregnancy due to potential effects on fetal growth and development.

Contraindicated for BPC-157: BPC-157 has not been adequately studied in human pregnancy. Its tissue-modulating effects may pose risks to fetal development.

Contraindicated for Thymosin Alpha-1: Immune modulation during pregnancy may disrupt the delicate immune tolerance required for fetal development.

Contraindicated for PT-141: PT-141 is contraindicated in pregnancy as melanocortin receptor activation may affect fetal development.

Contraindicated for AOD-9604: AOD-9604 has not been studied in pregnancy. Its effects on fetal metabolism are unknown.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 has not been studied in pregnancy. Its tissue-remodeling effects may pose risks to fetal development.

Contraindicated for GHK-Cu: GHK-Cu has not been studied in pregnancy. Copper peptide effects on fetal development are unknown.

Contraindicated for Epithalon (Epitalon): Epithalon has not been studied in pregnancy. Effects on fetal cellular development are unknown.

Contraindicated for Selank: Selank has not been studied in pregnancy. Its neuroactive effects may impact fetal brain development.

Contraindicated for Semax: Semax has not been studied in pregnancy. Its neuroactive and hormonal effects may affect fetal development.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP has not been studied in pregnancy. Its neuroendocrine effects may impact fetal development.

Contraindicated for MOTS-c: MOTS-c has not been studied in pregnancy. Its metabolic effects may impact fetal development.

Contraindicated for Tesamorelin: Tesamorelin is contraindicated in pregnancy due to potential effects on fetal growth from altered growth hormone levels.

Contraindicated for Hexarelin: Hexarelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for GHRP-6: GHRP-6 has not been studied in pregnancy. Growth hormone modulation may affect fetal development.

Contraindicated for GHRP-2: GHRP-2 has not been studied in pregnancy. Its effects on fetal growth and development are unknown.

Contraindicated for Melanotan II: Melanotan II is contraindicated in pregnancy due to unknown effects on fetal development from melanocortin receptor activation.

Contraindicated for LL-37: LL-37 has not been studied in pregnancy. Immune modulation may disrupt maternal-fetal immune tolerance.

Contraindicated for KPV: KPV has not been studied in pregnancy. Its immunomodulatory effects may impact fetal development.

Contraindicated for Dihexa: Dihexa has not been studied in pregnancy. Its neurotrophic and growth factor effects may impact fetal development.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ has not been studied in pregnancy. Its metabolic enzyme inhibition may affect fetal development.

Contraindicated for SS-31 (Elamipretide): SS-31 has not been studied in pregnancy. Its effects on mitochondrial function in developing tissues are unknown.

Contraindicated for PE-22-28: PE-22-28 has not been studied in pregnancy. Its neurogenic effects may impact fetal brain development.

Contraindicated for Kisspeptin-10: Kisspeptin-10 directly affects reproductive hormones and GnRH signaling. Use during pregnancy may disrupt hormonal balance critical for fetal development.

Contraindicated for Humanin: Humanin has not been studied in pregnancy. Its effects on fetal cellular development and apoptosis pathways are unknown.

Contraindicated for KLOW: KLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for GLOW: GLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for Retatrutide: Retatrutide has not been studied in pregnancy. GLP-1 receptor agonists may affect fetal development and maternal glucose regulation.

Contraindicated for CJC-1295: Safety of CJC-1295 during breastfeeding has not been established. Growth hormone modulation could affect lactation.

Contraindicated for BPC-157: Insufficient safety data exists for BPC-157 use during breastfeeding.

Contraindicated for PT-141: Safety of PT-141 during breastfeeding has not been established.

Contraindicated for AOD-9604: Insufficient safety data for AOD-9604 during breastfeeding.

Contraindicated for Selank: Safety of Selank during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): Safety of DSIP during breastfeeding has not been established.

Contraindicated for KPV: Safety of KPV during breastfeeding has not been established.

Contraindicated for 5-Amino-1MQ: Safety of 5-Amino-1MQ during breastfeeding has not been established.

Contraindicated for PE-22-28: Safety of PE-22-28 during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for Kisspeptin-10: Kisspeptin-10 modulates reproductive hormones, which may affect lactation and hormonal balance during breastfeeding.

Contraindicated for KLOW: Safety of KLOW during breastfeeding has not been established.

Contraindicated for GLOW: Safety of GLOW during breastfeeding has not been established.

Contraindicated for Retatrutide: Safety of Retatrutide during breastfeeding has not been established. It is unknown whether the peptide is excreted in breast milk.

Contraindicated for CJC-1295: Growth hormone elevation from CJC-1295 can worsen diabetic retinopathy by promoting abnormal blood vessel growth in the retina.

Contraindicated for Ipamorelin: Elevated growth hormone from Ipamorelin can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for GHRP-6: Elevated growth hormone from GHRP-6 can worsen diabetic retinopathy by promoting abnormal blood vessel growth.

Contraindicated for GHRP-2: Growth hormone elevation from GHRP-2 can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for Retatrutide: Rapid improvement in glycemic control from Retatrutide may temporarily worsen diabetic retinopathy. Close ophthalmologic monitoring is recommended.

Contraindicated for CJC-1295: Growth hormone-releasing peptides can elevate intracranial pressure, worsening existing intracranial hypertension.

Contraindicated for Sermorelin: Growth hormone elevation from Sermorelin can increase intracranial pressure.

Contraindicated for Tesamorelin: Growth hormone elevation from Tesamorelin can increase intracranial pressure.

Contraindicated for CJC-1295: CJC-1295 acts on the pituitary gland. Existing pituitary disorders may lead to unpredictable or dangerous hormone responses.

Contraindicated for Ipamorelin: Ipamorelin directly stimulates the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for Sermorelin: Sermorelin requires a functioning pituitary gland. Pituitary disorders may prevent proper response or cause adverse effects.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP affects neuroendocrine signaling involving the pituitary gland. Pre-existing pituitary conditions may lead to unpredictable effects.

Contraindicated for Tesamorelin: Tesamorelin acts directly on the pituitary gland. Pre-existing pituitary disorders may cause unpredictable hormonal responses.

Contraindicated for Hexarelin: Hexarelin acts on the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for GHRP-6: GHRP-6 acts directly on the pituitary gland. Pre-existing disorders may cause adverse hormonal effects.

Contraindicated for GHRP-2: GHRP-2 directly stimulates the pituitary gland. Pre-existing pituitary disorders may cause unpredictable responses.

Contraindicated for Kisspeptin-10: Kisspeptin-10 stimulates the hypothalamic-pituitary axis. Pre-existing pituitary disorders may lead to unpredictable hormonal responses.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 stimulates T-cell activity and immune response. In patients with autoimmune conditions, this can trigger disease flares.

Contraindicated for Epithalon (Epitalon): Epithalon may modulate immune function through its effects on the pineal gland, potentially exacerbating autoimmune conditions.

Contraindicated for Melanotan II: Melanotan II modulates immune function through melanocortin receptors, potentially exacerbating autoimmune conditions.

Contraindicated for LL-37: LL-37 is a potent immune activator. In autoimmune conditions, it may trigger inflammatory flares and worsen disease activity.

Contraindicated for KLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for GLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 enhances immune function, which directly counteracts immunosuppressive therapy required to prevent organ rejection.

Contraindicated for LL-37: LL-37 enhances immune function, which may counteract immunosuppressive therapy in transplant recipients.

Contraindicated for PT-141: PT-141 affects blood pressure and cardiovascular function. Patients with heart disease face increased risk of adverse cardiac events.

Contraindicated for Hexarelin: Hexarelin has been shown to affect cardiac function and cortisol release. Patients with cardiovascular disease should use caution.

Contraindicated for Melanotan II: Melanotan II affects cardiovascular function and can cause nausea and flushing. Heart disease patients should avoid use.

Contraindicated for PT-141: PT-141 can cause transient increases in blood pressure. Uncontrolled hypertension increases the risk of cardiovascular events.

Contraindicated for Semax: Semax can influence blood pressure regulation. Patients with uncontrolled hypertension should use caution.

Contraindicated for Melanotan II: Melanotan II can cause blood pressure fluctuations. Patients with uncontrolled hypertension face increased cardiovascular risk.

Contraindicated for Dihexa: Dihexa may influence cardiovascular function. Patients with uncontrolled hypertension should exercise caution.

Contraindicated for AOD-9604: Patients with severe kidney disease may have impaired clearance of AOD-9604 metabolites.

Contraindicated for MOTS-c: Patients with severe kidney disease may have impaired clearance of MOTS-c metabolites.

Contraindicated for 5-Amino-1MQ: Patients with kidney disease may have impaired clearance of 5-Amino-1MQ metabolites.

Contraindicated for SS-31 (Elamipretide): Patients with severe kidney disease may have impaired clearance of SS-31 and its metabolites.

Contraindicated for Retatrutide: Patients with severe kidney disease may have impaired clearance of Retatrutide. Dose adjustment or avoidance may be necessary.

Contraindicated for GHK-Cu: Copper metabolism is heavily dependent on liver function. Patients with liver disease may accumulate copper to toxic levels.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ affects metabolic enzyme pathways. Patients with liver disease may experience altered drug metabolism and increased toxicity risk.

Contraindicated for Retatrutide: Retatrutide is metabolized hepatically. Patients with significant liver impairment may experience altered drug levels and increased risk of adverse effects.

Contraindicated for Retatrutide: GLP-1 receptor agonists, including Retatrutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis should avoid use.

Contraindicated for BPC-157: BPC-157 affects the nitric oxide system and may influence blood clotting. Patients with clotting disorders should avoid use.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 can influence blood clotting pathways. Patients with clotting disorders or on anticoagulants should avoid use.

Contraindicated for Selank: Selank is derived from tuftsin, which can influence immune and coagulation pathways. Patients with clotting disorders should use caution.

Contraindicated for SS-31 (Elamipretide): SS-31 has been associated with injection site reactions. Patients with known peptide allergies should be monitored.

Contraindicated for KLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for GLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 directly opposes immunosuppressive medications, potentially causing dangerous drug interactions.

Contraindicated for LL-37: LL-37 stimulates immune responses, potentially opposing immunosuppressive medications.

Contraindicated for KPV: KPV has anti-inflammatory and immune-modulating effects that may interact with immunosuppressive medications.

Current Medications

List all medications, supplements, and treatments you are currently using.

Additional Notes

Medical Disclaimer

This screening questionnaire is for informational and pre-consultation purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation.

All peptide therapy protocols must be prescribed and supervised by a licensed healthcare provider. The contraindication information provided here is based on general clinical guidelines and may not reflect every individual’s unique medical circumstances.

Peptide therapies are used off-label in many cases. Results vary by individual. Borderfreehealth.com does not guarantee outcomes from any peptide therapy program.

By submitting this form, you acknowledge that a qualified medical professional will review your responses and determine appropriate treatment options. Do not discontinue any current medications or begin any new treatment based solely on the results of this screening.